Skip to main content
. 2022 May 4:NEJMoa2202261. doi: 10.1056/NEJMoa2202261

Figure 1. Screening, Randomization, Follow-up, and Analyses Performed up to the Second Data Cutoff Date of December 15, 2021.

Figure 1

Eight participants who had been randomly assigned to receive placebo and instead received at least one dose of ZF2001 (protocol violation) were included in the ZF2001 group in the safety analysis. Covid-19 denotes coronavirus disease 2019.